The impact of hypoxia on immune state in cancer

Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer

(2021) Keywan Mortezaee   JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY

Steps in metastasis: an updated review

(2021) Jamal Majidpoor et al.   MEDICAL ONCOLOGY

Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion

(2021) Nicole E. Scharping et al.   NATURE IMMUNOLOGY

CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells

(2021) Songyi Park et al.   Frontiers in Immunology

Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial

(2021) Akihito Kawazoe et al.   Lancet Gastroenterology & Hepatology

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours

(2021) Roberta Zappasodi et al.   NATURE

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2021) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modified Hypoxia-Inducible Factor Expression in CD8+ T Cells Increases Antitumor Efficacy

(2021) Pedro Veliça et al.   Cancer Immunology Research

Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy

(2021) Xin Peng et al.   Frontiers in Immunology

Organ tropism in solid tumor metastasis: an updated review

(2021) Keywan Mortezaee   Future Oncology

Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells

(2021) Ilkka Liikanen et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

(2021) Toni K. Choueiri et al.   NATURE MEDICINE

Metabolic changes of Interleukin-12/15/18-stimulated human NK cells

(2021) Iñigo Terrén et al.   Scientific Reports

The regulation of immune checkpoints by the hypoxic tumor microenvironment

(2021) Min Hu et al.   PeerJ

Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells

(2021) Nadia Bannoud et al.   Frontiers in Immunology

An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment

(2021) Raefa Abou Khouzam et al.   Frontiers in Immunology

Remodeling of Cancer-Specific Metabolism under Hypoxia with Lactate Calcium Salt in Human Colorectal Cancer Cells

(2021) Keun-Yeong Jeong et al.   Cancers

PD‐1‐induced proliferating T cells exhibit a distinct transcriptional signature

(2021) Marianne Strazza et al.   IMMUNOLOGY

Interleukin-2 therapy of cancer-clinical perspectives

(2021) Jamal Majidpoor et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Hypoxia Enhances the Expression of RNASET2 in Human Monocyte-Derived Dendritic Cells: Role of PI3K/AKT Pathway

(2021) Sara Monaci et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer

(2021) Sakshi Taneja et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure

(2021) T.C. Lam et al.   LUNG CANCER

Hypoxia‑induced lactate dehydrogenase A protects cells from apoptosis in endometriosis

(2021) Jinyan Zheng et al.   Molecular Medicine Reports

Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors

(2021) Anli Zhang et al.   Science Translational Medicine

Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors

(2021) Marcel A. Schneider et al.   Nature Communications

Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21

(2021) Xuan Lin et al.   Cancers

Perspectives on Hypoxia Signaling in Tumor Stroma

(2021) Yuqing Zhang et al.   Cancers

The Immunosuppressive Microenvironment in BRCA1-IRIS–Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages

(2020) Eman Sami et al.   CANCER RESEARCH

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

(2020) Per Pfeiffer et al.   LANCET ONCOLOGY

Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity

(2020) Dalton Hermans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis

(2020) Yaqing Zhang et al.   Cancer Discovery

Bcl2 inhibitor ABT737 reverses the Warburg effect via the Sirt3-HIF1α axis to promote oxidative stress-induced apoptosis in ovarian cancer cells

(2020) Delu Dong et al.   LIFE SCIENCES

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells

(2020) Zhe Wang et al.   PHARMACOLOGICAL RESEARCH

Hypoxia-Driven Immune Escape in the Tumor Microenvironment

(2020) Alyssa Vito et al.   Cells

The expressions of NLRP1, NLRP3, and AIM2 inflammasome complexes in the contusive spinal cord injury rat model and their responses to hormonal therapy

(2020) Jamal Majidpoor et al.   CELL AND TISSUE RESEARCH

Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer

(2020) Hong Xiang Zuo et al.   JOURNAL OF ETHNOPHARMACOLOGY

Natural killer cells in cancer biology and therapy

(2020) Song-Yang Wu et al.   Molecular Cancer

Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

(2020) Jackie E. Bader et al.   MOLECULAR CELL

Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors

(2020) Matthew I. Confeld et al.   MOLECULAR PHARMACEUTICS

Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway

(2020) Jukun Song et al.   Frontiers in Oncology

Toll-Iike Receptor-3 Activation Enhances Malignant Traits in Human Breast Cancer Cells Through Hypoxia-inducible Factor-1α

(2020) FRANCESCA SCATOZZA et al.   ANTICANCER RESEARCH

Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma

(2020) Hee Seung Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Dendritic cell biology and its role in tumor immunotherapy

(2020) Yingying Wang et al.   Journal of Hematology & Oncology

The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study

(2020) Masoud Najafi et al.   LIFE SCIENCES

AGE-RAGE synergy influences programmed cell death signaling to promote cancer

(2020) Bhargav N. Waghela et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

(2020) Shun Li et al.   NATURE

Dynamic regulation of hypoxia-inducible factor-1α activity is essential for normal B cell development

(2020) Natalie Burrows et al.   NATURE IMMUNOLOGY

HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice

(2020) Rouven Hoefflin et al.   Nature Communications

HIF-2α is indispensable for regulatory T cell function

(2020) Tzu-Sheng Hsu et al.   Nature Communications

Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy

(2020) Joseph M. Steingold et al.   Frontiers in Immunology

Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways

(2020) Yi-Na Liu et al.   Frontiers in Immunology

The Production of Pro-angiogenic VEGF-A Isoforms by Hypoxic Human NK Cells Is Independent of Their TGF-β-Mediated Conversion to an ILC1-Like Phenotype

(2020) Lindsey G. Hawke et al.   Frontiers in Immunology

Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development

(2020) Fatemeh Azizian-Farsani et al.   Frontiers in Oncology

Redox tolerance and metabolic reprogramming in solid tumors

(2020) Keywan Mortezaee   CELL BIOLOGY INTERNATIONAL

Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1α in cancer

(2020) Yu Fan Zhang et al.   PHYTOMEDICINE

Systemic hypoxia inhibits T cell response by limiting mitobiogenesis via matrix substrate-level phosphorylation arrest

(2020) Amijai Saragovi et al.   eLife

Acriflavine, a Potent Inhibitor of HIF-1α, Disturbs Glucose Metabolism and Suppresses ATF4-Protective Pathways in Melanoma under Non-Hypoxic Conditions

(2020) Román Martí-Díaz et al.   Cancers

Tumor Lactic Acidosis: Protecting Tumor by Inhibiting Cytotoxic Activity Through Motility Arrest and Bioenergetic Silencing

(2020) Angelika J. Fischbeck et al.   Frontiers in Oncology

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

(2019) Charles S Fuchs et al.   LANCET ONCOLOGY

No clear role for angiogenesis inhibitors in first-line therapy for stomach cancer

(2019) Annemieke Cats   LANCET ONCOLOGY

Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors

(2019) Anna Schurich et al.   Immunotherapy

Blocking TREM-1+ Tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-PD-L1 resistance in liver cancer

(2019) Qinchuan Wu et al.   HEPATOLOGY

A Phase 1b/2 Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer

(2019) James J Harding et al.   CLINICAL CANCER RESEARCH

Targeting hypoxia-induced carbonic anhydrase IX enhances immune checkpoint blockade locally and systemically

(2019) Shawn C Chafe et al.   Cancer Immunology Research

Hypoxia-induced VISTA promotes the suppressive function of myeloid- derived suppressor cells in the tumor microenvironment

(2019) Jie Deng et al.   Cancer Immunology Research

Dendritic Cells and Cancer: From Biology to Therapeutic Intervention

(2019) Wylie et al.   Cancers

The B-side of Cancer Immunity: The Underrated Tune

(2019) Largeot et al.   Cells

Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop

(2019) Ke Xu et al.   MOLECULAR THERAPY

Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma

(2019) Yancheng Yu et al.   DRUG DISCOVERY TODAY

Hypoxia enhances IL-10-producing B cell generation through upregulating high-mobility group B1 on tumor cell-released autophagosomes

(2019) Yue Zhang et al.   IMMUNOLOGY LETTERS

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

(2019) Roy S Herbst et al.   LANCET ONCOLOGY

Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges

(2019) Muhammad Zaeem Noman et al.   Cells

Targets for improving tumor response to radiotherapy

(2019) Keywan Mortezaee et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The 2019 Nobel Prize honors fundamental discoveries in hypoxia response

(2019) Javid Moslehi et al.   JOURNAL OF CLINICAL INVESTIGATION

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

(2019) Daniel P Petrylak et al.   LANCET ONCOLOGY

The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications

(2019) Ryota Tamura et al.   MEDICAL ONCOLOGY

Role of hypoxia in cancer therapy by regulating the tumor microenvironment

(2019) Xinming Jing et al.   Molecular Cancer

Microbe–MUC1 Crosstalk in Cancer-Associated Infections

(2019) Mukulika Bose et al.   TRENDS IN MOLECULAR MEDICINE

Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1α and HIF-2α

(2019) Keywan Mortezaee   LIFE SCIENCES

Stromal reprogramming: A target for tumor therapy

(2019) Masoud Najafi et al.   LIFE SCIENCES

Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion

(2019) Nicholas C. DeVito et al.   Frontiers in Immunology

SIRT1 and HIF1α signaling in metabolism and immune responses

(2018) Qing Yu et al.   CANCER LETTERS

Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer

(2018) Lifeng Li et al.   CANCER RESEARCH

TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy

(2018) Lan Huang et al.   Cellular & Molecular Immunology

Hypoxia and acidosis: immune suppressors and therapeutic targets

(2018) Sultan Damgaci et al.   IMMUNOLOGY

Oxygen-dependent regulation of immune checkpoint mechanisms

(2018) Akio Ohta   INTERNATIONAL IMMUNOLOGY

Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy

(2018) Hiroaki Senju et al.   International Journal of Biological Sciences

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

(2018) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

(2018) Janet Retseck et al.   Journal of Translational Medicine

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy

(2018) Yiliang Li et al.   Frontiers in Immunology

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Disruption of the redox balance with either oxidative or anti-oxidative overloading as a promising target for cancer therapy

(2018) Bagher Farhood et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Targeting the IDO1 pathway in cancer: from bench to bedside

(2018) Ming Liu et al.   Journal of Hematology & Oncology

Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation

(2018) Arum Park et al.   Frontiers in Immunology

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression

(2018) Christopher Groth et al.   BRITISH JOURNAL OF CANCER

Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches

(2018) Nasser Hashemi Goradel et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Effects of curcumin on hypoxia-inducible factor as a new therapeutic target

(2018) Afsane Bahrami et al.   PHARMACOLOGICAL RESEARCH

T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses

(2018) Alireza Saeidi et al.   Frontiers in Immunology

NADPH oxidase as a target for modulation of radiation response; implications to carcinogenesis and radiotherapy

(2018) Keywan Mortezaee et al.   Current Molecular Pharmacology

Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer

(2017) Mao Lin et al.   IMMUNOLOGY LETTERS

Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma

(2017) Takafumi Minami et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

(2017) Daniel P Petrylak et al.   LANCET

Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma

(2017) David Kung-Chun Chiu et al.   Nature Communications

Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis

(2017) Ewelina Krzywinska et al.   Nature Communications

CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function

(2017) Xi Chen et al.   Oncotarget

Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis

(2017) Erika M. Palmieri et al.   Cell Reports

CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer

(2017) Jieyao Li et al.   OncoImmunology

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

(2016) R. Obermannová et al.   ANNALS OF ONCOLOGY

Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer

(2016) Nasim Kheshtchin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26

(2016) David Kung-Chun Chiu et al.   HEPATOLOGY

CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation

(2016) Vinit Kumar et al.   IMMUNITY

Glycolysis determines dichotomous regulation of T cell subsets in hypoxia

(2016) Yang Xu et al.   JOURNAL OF CLINICAL INVESTIGATION

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

(2016) Alain Ravaud et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dendritic Cells and Cancer Immunity

(2016) Alycia Gardner et al.   TRENDS IN IMMUNOLOGY

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment

(2016) Shengwei Han et al.   Oncotarget

Hypoxia and antitumor CD8+ T cells: An incompatible alliance?

(2016) Romain Vuillefroy de Silly et al.   OncoImmunology

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

Carbonic Anhydrase IX Promotes Myeloid-Derived Suppressor Cell Mobilization and Establishment of a Metastatic Niche by Stimulating G-CSF Production

(2015) S. C. Chafe et al.   CANCER RESEARCH

HIF-1 at the crossroads of hypoxia, inflammation, and cancer

(2015) Kuppusamy Balamurugan   INTERNATIONAL JOURNAL OF CANCER

Does ramucirumab deserve a second chance for liver cancer?

(2015) Alejandro Forner et al.   LANCET ONCOLOGY

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model

(2015) Tao Yin et al.   ONCOLOGY RESEARCH

Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia

(2015) K. E. Lee et al.   Cancer Discovery

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?

(2015) Simon Ville et al.   Frontiers in Immunology

HIF-1α pathway: role, regulation and intervention for cancer therapy

(2015) Georgina N. Masoud et al.   Acta Pharmaceutica Sinica B

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma

(2015) Tiansuo Zhao et al.   Oncotarget

RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis

(2015) Mathias Dahlmann et al.   Oncotarget

Toll-like Receptor 3 Regulates Angiogenesis and Apoptosis in Prostate Cancer Cell Lines through Hypoxia-Inducible Factor 1α

(2015) Alessio Paone et al.   NEOPLASIA

Mechanisms of Hypoxia-Mediated Immune Escape in Cancer

(2014) I. B. Barsoum et al.   CANCER RESEARCH

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts

(2014) M. Ammirante et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer

(2014) R Kang et al.   Cell Death & Disease

Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro

(2014) JOUKO SANDHOLM et al.   Oncology Letters

Cancer: A Tale of Aberrant PRR Response

(2014) Raunaq Singh Nagi et al.   Frontiers in Immunology

A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells

(2013) I. B. Barsoum et al.   CANCER RESEARCH

SIRT1 Limits the Function and Fate of Myeloid-Derived Suppressor Cells in Tumors by Orchestrating HIF-1 -Dependent Glycolysis

(2013) G. Liu et al.   CANCER RESEARCH

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen

(2013) Andrew L Doedens et al.   NATURE IMMUNOLOGY

Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment

(2012) Koichi Ito et al.   CANCER AND METASTASIS REVIEWS

AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo

(2012) Brandon Faubert et al.   Cell Metabolism

Hypoxia-inducible factor as a therapeutic target for cardioprotection

(2012) Sang-Ging Ong et al.   PHARMACOLOGY & THERAPEUTICS

Targeting pattern recognition receptors in cancer immunotherapy

(2012) Nadège Goutagny et al.   Targeted Oncology

Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression

(2011) M. Z. Noman et al.   CANCER RESEARCH

The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells

(2011) E. Narni-Mancinelli et al.   INTERNATIONAL IMMUNOLOGY

Hypoxia-Dependent Inhibition of Tumor Cell Susceptibility to CTL-Mediated Lysis Involves NANOG Induction in Target Cells

(2011) Meriem Hasmim et al.   JOURNAL OF IMMUNOLOGY

Macrophage Expression of Hypoxia-Inducible Factor-1  Suppresses T-Cell Function and Promotes Tumor Progression

(2010) A. L. Doedens et al.   CANCER RESEARCH

Knockout of HIF-1  in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses

(2010) C. Werno et al.   CARCINOGENESIS

CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts

(2010) Begoña Santiago et al.   CYTOKINE

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

(2010) Cesar A. Corzo et al.   JOURNAL OF EXPERIMENTAL MEDICINE

HIF-1: upstream and downstream of cancer metabolism

(2009) Gregg L Semenza   CURRENT OPINION IN GENETICS & DEVELOPMENT